The Motley Fool··Adria CiminoTwo Biotech Leaders Poised for Growth in 2026: REGN and VERX
Regeneron and Vertex Pharmaceuticals emerge as compelling 2026 biotech investments, with REGN valued at 17x and VERX at 24x forward earnings, offering growth and stability respectively.
VRTXREGNpharmaceutical growthinvestment recommendation